What’s really holding back healthcare M&A?

Healthcare M&A Is Poised for a Recovery in 2026. The Industry Still Sees Three Structural Barriers Standing in the Way.

Healthcare dealmaking enters 2026 with improving sentiment, lower financing pressure, and renewed appetite from both strategics and private equity. But according to a proprietary Healthcare150 survey of 160 healthcare executives, investors, and operators, the path to a true M&A rebound remains far from clear.

When asked about the single biggest barrier to healthcare M&A acceleration in 2026, respondents pointed to three nearly equal constraints: regulatory and antitrust scrutiny (37%), valuation gaps between buyers and sellers (32%), and a shortage of scalable, high-quality assets (31%).

The close distribution matters.

It suggests healthcare M&A is no longer being held back by one cyclical issue such as interest rates or financing availability. Instead, the market is facing structural friction across regulation, pricing expectations, and asset quality simultaneously.

Regulatory scrutiny remains the dominant concern.

Over the past several years, the FTC and DOJ have taken a far more aggressive stance toward healthcare consolidation, particularly across physician practice management, payer-provider integration, home health, and technology-enabled services. Transactions that previously may have cleared with minimal resistance are now facing extended review periods, additional disclosure requests, and growing uncertainty around approval outcomes.

Even when deals close, the process has become materially slower and more expensive.

For buyers, that creates a difficult underwriting environment. Longer review timelines increase financing exposure, delay integration planning, and create operational drift inside target businesses. For private equity firms operating against fund timelines and return thresholds, regulatory uncertainty increasingly acts as a hidden cost of capital.

The impact is especially pronounced in larger platform acquisitions, where scale itself can trigger scrutiny.

At the same time, the market continues to struggle with valuation alignment.

Many sellers remain anchored to pricing expectations established during the peak 2020–2021 healthcare investment cycle, when capital was abundant, growth rates accelerated, and digital health multiples expanded rapidly. Buyers, however, are evaluating assets in a far different environment defined by labor inflation, reimbursement pressure, slower utilization growth, and tighter operating margins.

That disconnect has widened the bid-ask spread across healthcare services and healthtech.

Strategic acquirers are still willing to pay premiums for differentiated assets, but the definition of “differentiated” has changed. Growth alone is no longer enough. Buyers increasingly want visibility into recurring revenue durability, payer diversification, physician retention, compliance infrastructure, and EBITDA quality before stretching on valuation.

The result is a market where transaction volume may improve in 2026, but discipline is likely to remain high.

The third survey finding may ultimately prove the most important long term.

Nearly one-third of respondents identified a lack of scalable, high-quality assets as the biggest obstacle to M&A acceleration. That points to a broader structural issue inside healthcare: many companies achieved rapid expansion during the pandemic-era funding environment, but fewer have demonstrated operational durability at scale.

This is particularly relevant in digital health and tech-enabled care delivery, where growth often outpaced infrastructure maturity. Investors are now prioritizing businesses with proven integration capabilities, measurable outcomes, stable reimbursement exposure, and operational systems capable of supporting consolidation strategies.

In many subsectors, there are simply fewer assets that meet institutional-quality standards than the market expected three years ago.

That dynamic may reshape the next phase of healthcare consolidation.

Rather than broad-based deal expansion, 2026 could become a bifurcated market where premium assets continue commanding strong valuations while lower-quality operators struggle to attract strategic interest. Scale alone may no longer drive pricing power. Execution quality increasingly will.

The broader takeaway is that healthcare M&A is not constrained by lack of interest or available capital. Strategic buyers remain active across pharma, medtech, healthcare IT, and provider services. Private equity firms continue sitting on significant dry powder earmarked for healthcare deployment.

What the market lacks is clarity.

Clarity around regulation. Clarity around sustainable valuations. And clarity around which healthcare businesses can truly scale in a more disciplined operating environment.

The next healthcare M&A cycle will likely happen. But unlike prior rebounds fueled by abundant capital and aggressive multiple expansion, 2026 may reward a different set of winners.

Not the fastest-growing companies.

The most defensible ones.